The primary purpose of this study was to evaluate the event-based prospective memory (EBPM) and time-based prospective memory (TBPM) in androgen-deprivation therapy (ADT)-induced cognitive impairment in patients with prostate cancer (PC).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Participants included PC patients who had undergone ADT (ADT group, n = 43) or patients who did not undergo ADT (non-ADT group, n = 35), as well as age and education-matched healthy controls (HC group, n = 40). All participants were administered with a battery of neuropsychological tests including EBPM and TBPM tasks. Our results indicated that during the EBPM task, the ADT group obtained significantly lower scores than the non-ADT and HC group did, while no significant differences in the TBPM task scores were found among these three groups. Additionally, the ADT group demonstrated significantly lower scores in several cognitive tasks, including attention, memory, and information processing, when compared with the other two groups. This study demonstrated that PC patients receiving ADT may have selective reductions in EBPM performance but unimpaired TBPM performance and that these deficits may result from the changes of function and structure of the pre-frontal cortex induced by ADT.
Yang J, Zhong F, Qiu J, Cheng H, Wang K. Are you the author?
Department of Neurology, Anhui Provincial Hospital, Hefei, China; Laboratory of Neuropsychology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Reference: Eur J Cancer Care (Engl). 2015 Mar;24(2):198-204.